Claims for Patent: 9,669,107

Summary for Patent: 9,669,107

Title:	Antibody-active agent conjugates and methods of use
Abstract:	The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).
Inventor(s):	Kim; Yongzu (Daejeon, KR), Park; Taekyo (Daejeon, KR), Woo; Sungho (Daejeon, KR), Lee; Hyangsook (Daejeon, KR), Kim; Sunyoung (Daejeon, KR), Cho; Jongun (Daejeon, KR), Jung; Doohwan (Daejeon, KR), Kim; Youngun (Daejeon, KR), Kwon; Hyunjin (Daejeon, KR), Oh; Kyuman (Daejeon, KR), Chung; Yunseo (Daejeon, KR), Park; Yun-Hee (Daejeon, KR)
Assignee:	LegoChem Biosciences, Inc. (Daejeon, KR)
Application Number:	14/517,616
Patent Claims:	1. An antibody-active agent conjugate comprising: (a) a full-length antibody comprising two immunoglobulin heavy chains and two immunoglobulin light chains, wherein the antibody recognizes and specifically binds to a target through at least one antigen recognition site; (b) at least one amino acid motif having an amino acid sequence CAAX, wherein C represents cysteine, A represents an aliphatic amino acid, and X represents an amino acid that determines a substrate specificity of the isoprenoid transferase, directly or indirectly linked to a carboxy terminus of a heavy chain or light chain of the antibody, wherein the amino acid motif is recognizable by an isoprenoid transferase; (c) an isosubstrate directly linked to a cysteine moiety of the at least one amino acid motif, wherein the isosubstrate contains at least one isoprenoid unit and is recognizable by the isoprenoid transferase; and (d) at least one active agent, wherein the active agent is a toxin, and the toxin is directly or indirectly linked to the isosubstrate. 2. The conjugate of claim 1, wherein the antibody is a polyclonal antibody, a monoclonal antibody, a multispecific antibody, a bispecific antibody, a chimeric antibody, a humanized antibody, or a human antibody. 3. The antibody-active agent conjugate of claim 1, wherein the amino acid motif is directly or indirectly linked to the carboxy terminus of an immunoglobulin heavy chain. 4. The antibody-active agent conjugate of claim 1, wherein the amino acid motif is directly or indirectly linked to the carboxy terminus of an immunoglobulin light chain. 5. The antibody-active agent conjugate of claim 1, wherein a second amino acid motif is directly or indirectly linked to a second carboxy terminus. 6. The antibody-active agent conjugate of claim 1, wherein the at least one amino acid motif is indirectly linked to the carboxy terminus of the heavy chain or the light chain via a spacer group. 7. The conjugate of claim 6, wherein the spacer group comprises at least one amino acid. 8. The conjugate of claim 6, wherein the spacer group comprises at least one glycine. 9. The antibody-active agent conjugate of claim 8, wherein the spacer group comprises seven consecutive glycine residues. 10. The antibody-active agent conjugate of claim 1, wherein the isosubstrate is indirectly linked to the at least one active agent via at least one linker. 11. The antibody-active agent conjugate of claim 10, wherein the linker is a linear linker. 12. The antibody-active agent conjugate of claim 11, wherein the linear linker is directly linked to the at least one active agent. 13. The antibody-active agent conjugate of claim 10, wherein the linker is a linker having branches. 14. The antibody-active agent conjugate of claim 13, wherein one or more of the branches are directly linked to at least one of the active agents. 15. The antibody-active agent conjugate of claim 13, wherein at least two of the branches are directly linked to different active agents. 16. The antibody-active agent conjugate of claim 10, wherein the linker is a cleavable linker. 17. The conjugate of claim 16, wherein the linker is a chemically cleavable linker, an enzymatically cleavable linker, a hydrolysable linker, or a combination thereof. 18. The antibody-active agent conjugate of claim 17, wherein the cleavable linker is an enzymatically cleavable linker and the enzymatically cleavable linker contains a peptide that can be cleaved by cathepsin B or a glucuronide that can be cleaved by .beta.-glucuronidase. 19. The antibody-active agent conjugate of claim 1, wherein the toxin is diphtheria toxin, botulinum toxin, tetanus toxin, dysentery toxin, cholera toxin, .alpha.-amanitin, a pyrrolobenzodiazepine, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, tubulysin, geldanamycin, maytansinoid, calicheamicin, daunomycin, doxorubicin, vindesine, SG2285, dolastatin, auristatin, cryptophycin, camptothecin, a rhizoxin, duocarmycin, an enediyne antibiotic, esperamicin, epothilone, a toxoid, or a combination of any of the foregoing. 20. The antibody-active agent conjugate of claim 1, wherein the conjugate is trastuzumab-LC-G.sub.7CVIM-BG-MMAF, trastuzumab-LC-G.sub.7C-BG-MMAF, trastuzumab-LC-G.sub.7CVIM-VC-MMAF-OMe, trastuzumab-LC-G.sub.7C-VC-MMAF-OMe, trastuzumab-LC-G.sub.7CVIM-BG-MMAE, or trastuzumab-LC-G.sub.7C-BG-MMAE, wherein LC indicates that the following amino acid sequence is linked to the light chain of the indicated antibody, G.sub.7 represents a series of seven glycine units, VC represents a Val-Cit linker, and BG represents a beta-glucuronide linker. 21. The antibody-active agent conjugate of claim 1, wherein the amino acid motif is CVIM (SEQ ID NO:28) or CVLL (SEQ ID NO:29). 22. An antibody-active agent conjugate, wherein the conjugate is trastuzumab-LC-G.sub.7CVIM-BG-MMAF, trastuzumab-LC-G.sub.7C-BG-MMAF, trastuzumab-LC-G.sub.7CVIM-VC-MMAF-OMe, trastuzumab-LC-G.sub.7C-VC-MMAF-OMe, trastuzumab-LC-G.sub.7CVIM-BG-MMAE, or trastuzumab-LC-G.sub.7C-BG-MMAE, wherein LC indicates that the following amino acid sequence is linked to the light chain of the indicated antibody, G.sub.7 represents a series of seven glycine units, VC represents a Val-Cit linker, and BG represents a beta-glucuronide linker. 23. The antibody-active agent conjugate of claim 1, wherein the at least one active agent is directly or indirectly linked to the isosubstrate by an oxime. 24. The antibody-active agent conjugate of claim 10, wherein the linker is a non-cleavable linker. 25. The antibody-active agent conjugate of claim 11, wherein the linear linker is directly linked to the at least two different active agents.

Details for Patent 9,669,107

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-05-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-05-08
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2031-05-08